Lv51
892 积分 2025-03-09 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
14分钟前
待确认
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
16分钟前
待确认
CAMPASS: Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC)—A randomized, single-blind, multicenter phase 3 study
41分钟前
待确认
A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3
45分钟前
待确认
EP.11.17 Promising Effect of Nivolumab With Carboplatin, Paclitaxel, and Bevacizumab in EGFR-Mutant NSCLC Following EGFR-TKI Therapy
1小时前
求助中
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
1个月前
已完结
Non‐small cell lung cancer in China
1个月前
已完结
Non–Small Cell Lung Cancer, Version 4.2024
1个月前
已完结
Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer
1个月前
已完结
Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives
1个月前
已完结
皖公网安备34019202002308
